Evidence map›Paper›PMID 29299160›Full record

ArticleOncotarget2017

Detection of prognostic methylation markers by methylC-capture sequencing in acute myeloid leukemia.

Yan Li, Hongmei Zhao, Qingyu Xu, Na Lv, Yu Jing, Lili Wang, Xiaowen Wang, Jing Guo, Lei Zhou, Jing Liu and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Yan Li *Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Hongmei Zhao *Annoroad Gene Technology Co. Ltd., Beijing 100176, China.
Qingyu Xu *Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Na LvDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Yu JingDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Lili WangDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Xiaowen WangAnnoroad Gene Technology Co. Ltd., Beijing 100176, China.
Jing GuoAnnoroad Gene Technology Co. Ltd., Beijing 100176, China.
Lei ZhouDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Jing LiuDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Guofeng ChenDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Chongjian ChenAnnoroad Gene Technology Co. Ltd., Beijing 100176, China.
Yonghui LiDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Li YuDepartment of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 100853, China.
Chinese PLA General Hospital · CNAnnoroad Gene Technology (China) · CNNankai University · CNHainan Branch of People's Liberation Army General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical and genetic features incompletely predict outcome in acute myeloid leukemia (AML). The value of clinical methylation assays for prognostic markers has not been extensively explored. We assess the prognostic implications of methylC-capture sequencing (MCC-Seq) in patients with de novo AML by integrating DNA methylation and genetic risk stratification. MCC-Seq assessed DNA methylation level in 44 samples. The differentially methylated regions associated with prognostic genetic information were identified. The selected prognostic DNA methylation markers were independently validated in two sets. MCC-Seq exhibited good performance in AML patients. A panel of 12 differentially methylated genes was identified with promoter hyper-differentially methylated regions associated with the outcome. Compared with a low M-value, a high M-value was associated with failure to achieve complete remission (

Indexed as

acute myeloid leukemiaDNA methylationMCC-Seqnext generation sequencingprognostic markers

Identifiers

PMID29299160
PMCPMC5746395
OpenAlexW2773263154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.